ATRA + Arsenic Trioxide (APL low/intermediate-risk) — APL0406 / LO-CoCo schedule

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-ATRA` `DRUG-ATO`

ID	`REG-ATRA-ATO-APL`
Type	Regimen
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-APL0406-LOCOCO-2013` `SRC-ELN-APL-2019` `SRC-NCCN-AML-2025`

Notes

Standard 1L for low/intermediate-risk APL (Sanz WBC ≤10). APL0406: 2-y EFS 97% vs 86% with ATRA+chemo (AIDA), OS 99% vs 91%, less hematologic toxicity, no anthracycline cardiotoxicity. ATRA initiated IMMEDIATELY at clinical APL suspicion (do NOT wait for cytogenetic confirmation). Daily ECG + electrolyte protocol mandatory during ATO induction. STUB — requires clinical co-lead signoff before publication.

Used By

Indication

IND-APL-1L-ATRA-ATO - IND-APL-1L-ATRA-ATO